There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Verona Pharma Plc (NASDAQ:VRNA) and Jazz Pharmaceuticals (NASDAQ:JAZZ) with bullish sentiments.
Verona Pharma Plc (VRNA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Verona Pharma Plc, with a price target of $56. The company’s shares opened today at $13.50.
According to TipRanks.com, Moussatos is a 1-star analyst with an average return of -0.3% and a 41.6% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as Allena Pharmaceuticals Inc, Aquestive Therapeutics Inc, and Catabasis Pharmaceuticals.
Currently, the analyst consensus on Verona Pharma Plc is a Moderate Buy with an average price target of $41.
See today’s analyst top recommended stocks >>
Jazz Pharmaceuticals (JAZZ)
B.Riley FBR analyst David Buck reiterated a Buy rating on Jazz Pharmaceuticals today and set a price target of $219. The company’s shares opened today at $162.97.
Buck noted:
“We reiterate our Buy rating for Jazz Pharmaceuticals plc (JAZZ), our top pick and Alpha Generator, with our $219 PT. We see attractive valuation for JAZZ shares at 12.3x our 2018E EPS estimate of $13.15 and 10.4x our 2019E EPS estimate of $15.65. Jazz held a webcast update for its Vyxeos EU launch on and we highlight takeaways. First, the EU is nearly as key as the US market with an estimated 20,000 diagnosed AML leukemia cases annually with drug treated cases representing 10,000 and about 8,000 patients excluding clinical trials. The EU AML population that coincides with the label is about 3,000-4,000.”
According to TipRanks.com, Buck is a 4-star analyst with an average return of 15.7% and a 64.3% success rate. Buck covers the Healthcare sector, focusing on stocks such as Corcept Therapeutics Inc, Spectrum Pharmaceuticals, and Supernus Pharmaceuticals.
Currently, the analyst consensus on Jazz Pharmaceuticals is a Strong Buy with an average price target of $204, representing a 25.2% upside. In a report released yesterday, BMO Capital also maintained a Buy rating on the stock with a $206 price target.
.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
